Association of house spraying with suppressed levels of drug resistance in Zimbabwe

Malaria Journal

Volumn 3, Issue , 2004, Pages

  Mharakurwa, Sungano ^a,b   Mutambu, Susan L ^c   Mudyiradima, Robert ^d   Chimbadzwa, Tawanda ^d   Chandiwana, Steven K ^e   Day, Karen P ^f  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Malaria Institute at Macha   (Zambia)

^c Blair Research Institute   (Zimbabwe)

^d Box 323 ^*  (Zimbabwe)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; PYRIMETHAMINE; SULFADOXINE;

ADULT; ARTICLE; BACTERIAL TRANSMISSION; DISEASE ASSOCIATION; HUMAN; MALARIA FALCIPARUM; MEDICAL ASSESSMENT; PROBABILITY; REDUCTION; RISK FACTOR; ZIMBABWE;

ANIMALS; ANTIMALARIALS; ATP-BINDING CASSETTE TRANSPORTERS; CHLOROQUINE; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE; GENES, MDR; GENOTYPE; HOUSING; HUMANS; INCIDENCE; INSECTICIDES; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; MOSQUITO CONTROL; MUTATION; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PROBABILITY; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS; TREATMENT FAILURE; ZIMBABWE;

EID: 12244311261     PISSN: 14752875     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2875-3-35     Document Type: Article

References (43)

1. Wernsdorfer WH, Payne D: The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther 1991, 50:95-121.
2. Wernsdorfer WH: Epidemiology of drug resistance in malaria. Acta Trop 1994, 56:143-156.
3. D'Alessandro U, Buttiens H: History and importance of antimalarial drug resistance. Trop Med Int Health 2001, 6:845-848.
4. Trape JF: The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 2001, 64:12-17.
5. Trape JF, Pison G, Spiegel A, Enel C, Rogier C: Combating malaria in Africa. Trends Parasitol 2002, 18:224-230.
6. Gorissen E, Ashruf G, Lamboo M, Bennebroek J, Gikunda S, Mbaruku G, Kager PA: In vivo efficacy study of amodiaquine and sulfadoxine/pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. Trop Med Int Health 2000, 5:459-463.
7. Bijl HM, Kager J, Koetsier DW, van der Werf TS: Chloroquine- and sulfadoxine-pyrimethamine-resistant Falciparum malaria in vivo - a pilot study in rural Zambia. Trop Med Int Health 2000, 5:692-695.
8. Bwijo B, Kaneko A, Takechi M, Zungu IL, Moriyama Y, Lum JK, Tsukahara T, Mita T, Takahashi N, Bergqvist Y, Bjorkman A, Kobayakawa T: High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop 2003, 85:363-373.
9. White N: Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: sulfadoxine-pyrimethamine is not working in Malawi. Bmj 2004, 328:1259; author reply 1260.
10. Olliaro PL, Trigg PI: Status of antimalarial drugs under development. Bull World Health Organ 1995, 73:565-571.
11. Olliaro PL, Taylor WR: Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review. J Postgrad Med 2004, 50:40-44.
12. Foote SJ, Cowman AF: The mode of action and the mechanism of resistance to antimalarial drugs. Acta Trop 1994, 56:157-171.
13. Dua VK, Dev V, Phookan S, Gupta NC, Sharma VP, Subbarao SK: Multi-drug resistant Plasmodium falciparum malaria in Assam, India: timing of recurrence and anti-malarial drug concentrations in whole blood. Am J Trop Med Hyg 2003, 69:555-557.
14. Giao PT, de Vries PJ, Hung le Q, Binh TQ, Nam NV, Kager PA: CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquoneproguanil against falciparum malaria in Vietnam. Trop Med Int Health 2004, 9:209-216.
15. Wattanakoon Y, Chittamas S, Pornkulprasit V, Kanda T, Thimasarn K, Rojanawatsirivej C, Looareesuwan S, Bunnag D: Six-years monitoring the efficacy of the combination of artesunate and mefloquine for the treatment of uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health 2003, 34:542-545.
16. Peters W: The prevention of antimalarial drug resistance. Pharmacol Ther 1990, 47:499-508.
17. White N: Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 1999, 354:739-749.
18. David KP, Alifrangis M, Salanti A, Vestergaard LS, Ronn A, Bygbjerg IB: Atovaquone/proguanil resistance in Africa: a case report. Scand J Infect Dis 2003, 35:897-898.
19. Schwartz E, Bujanover S, Kain KC: Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis 2003, 37:450-451.
20. Farnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, Lindegardh N, Berezcky S, Bjorkman A: Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. Bmj 2003, 326:628-629.
21. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G: Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 2002, 1:1.
22. Crabb C: Plasmodium falciparum outwits Malarone, protector of travellers. Bull World Health Organ 2003, 81:382-383.
23. Hastings IM: A model for the origins and spread of drug-resistant malaria. Parasitology 1997, 115 (Pt 2):133-141.
24. Hastings IM, Mackinnon MJ: The emergence of drug-resistant malaria. Parasitology 1998, 117 (Pt 5):411-417.
25. Ariey F, Robert V: The puzzling links between malaria transmission and drug resistance. Trends Parasitol 2003, 19:158-60; author reply 160-1.
26. Schmidt KF: Malaria research. Inbred parasites may spur resistance. Science 1995, 269:1670.
27. Molyneux DH, Floyd K, Barnish G, Fevre EM: Transmission control and drug resistance in malaria: a crucial interaction. Parasitol Today 1999, 15:238-240.
28. Taylor P, Mutambu SL: A review of the malaria situation in Zimbabwe with special reference to the period 1972-1981. Trans R Soc Trop Med Hyg 1986, 80:12-19.
29. Herd N, Jordan T: An investigation of malaria during pregnancy in Zimbabwe. Cent Afr J Med 1981, 27:62-68.
30. Taylor P, A. Taputaira: Forty years of malaria control in Zimbabwe. In Proceedings of the First National Symposium of Science and Technology Harare; 1988.
31. WHO: Assessment of the Therapeutic Efficacy of Antimalarial Drugs for the Treatment of Uncomplicated Malaria in Africa in Areas with Intense Transmission. Geneva, World Health Organization; 1996.
32. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ, Cowman AF: Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 1990, 345:255-258.
33. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LMB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the Plasmodium falciparum digestive vacuole transmembrane protein Pfcrtand evidence for their role in chloroquine resistance. Molecular Cell 2000, 6:861-871.
34. Frean JA, el Kariem FM, Warhurst DC, Miles MA: Rapid detection of pfmdr1 mutations in chloroquine-resistant Plasmodium falciparum malaria by polymerase chain reaction analysis of blood spots. Trans R Soc Trop Med Hyg 1992, 86:29-30.
35. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, Greenwood BM, Warhurst DC: Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology 1997, 114 (Pt 3):205-211.
36. Dye C, Williams BG: Multigenic drug resistance among inbred malaria parasites. Proc R Soc Lond B Biol Sci 1997, 264:61-67.
37. Talisuna AO, Langi P, Mutabingwa TK, Van Marck E, Speybroeck N, Egwang TG, Watkins WW, Hastings IM, D'Alessandro U: Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria. Int J Parasitol 2003, 33:1051-1058.
38. Liu DQ, Liu RJ, Ren DX, Gao DQ, Zhang CY, Qui CP, Cai XZ, Ling CF, Song AH, Tang X: Changes in the resistance of Plasmodium falciparum to chloroquine in Hainan, China. Bull World Health Organ 1995, 73:483-486.
39. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Bjorkman A: Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg 2003, 68:413-415.
40. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV: Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 2003, 187:1870-1875.
41. Talisuna AO, Langi P, Bakyaita N, Egwang T, Mutabingwa TK, Watkins W, Van Marck E, D'Alessandro U: Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors? Trans R Soc Trop Med Hyg 2002, 96:310-317.
42. Hastings IM: Malaria control and the evolution of drug resistance: an intriguing link. Trends Parasitol 2003, 19:70-73.
43. Yamey G: Roll Back Malaria: a failing global health campaign. Bmj 2004, 328:1086-1087.